271 related articles for article (PubMed ID: 35076099)
1. Medium branched chain fatty acids improve the profile of tricarboxylic acid cycle intermediates in mitochondrial fatty acid β-oxidation deficient cells: A comparative study.
Karunanidhi A; Van't Land C; Rajasundaram D; Grings M; Vockley J; Mohsen AW
J Inherit Metab Dis; 2022 May; 45(3):541-556. PubMed ID: 35076099
[TBL] [Abstract][Full Text] [Related]
2. Heptanoic and medium branched-chain fatty acids as anaplerotic treatment for medium chain acyl-CoA dehydrogenase deficiency.
Karunanidhi A; Basu S; Zhao XJ; D'Annibale O; Van't Land C; Vockley J; Mohsen AW
Mol Genet Metab; 2023 Nov; 140(3):107689. PubMed ID: 37660571
[TBL] [Abstract][Full Text] [Related]
3. Cardiac tissue citric acid cycle intermediates in exercised very long-chain acyl-CoA dehydrogenase-deficient mice fed triheptanoin or medium-chain triglyceride.
Gaston G; Gangoiti JA; Winn S; Chan B; Barshop BA; Harding CO; Gillingham MB
J Inherit Metab Dis; 2020 Nov; 43(6):1232-1242. PubMed ID: 33448436
[TBL] [Abstract][Full Text] [Related]
4. Long-chain fatty acid oxidation during early human development.
Oey NA; den Boer ME; Wijburg FA; Vekemans M; Augé J; Steiner C; Wanders RJ; Waterham HR; Ruiter JP; Attié-Bitach T
Pediatr Res; 2005 Jun; 57(6):755-9. PubMed ID: 15845636
[TBL] [Abstract][Full Text] [Related]
5. Impact of newborn screening for fatty acid oxidation disorders on neurological outcome: A Belgian retrospective and multicentric study.
Everard E; Laeremans H; Boemer F; Marie S; Vincent MF; Dewulf JP; Debray FG; De Laet C; Nassogne MC
Eur J Paediatr Neurol; 2024 Mar; 49():60-65. PubMed ID: 38377647
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of mitochondrial long chain fatty acid oxidation and carnitine defects from a single center metabolic genetics clinic.
Ambrose A; Sheehan M; Bahl S; Athey T; Ghai-Jain S; Chan A; Mercimek-Andrews S
Orphanet J Rare Dis; 2022 Sep; 17(1):360. PubMed ID: 36109795
[TBL] [Abstract][Full Text] [Related]
7. De novo fatty acid biosynthesis and elongation in very long-chain acyl-CoA dehydrogenase-deficient mice supplemented with odd or even medium-chain fatty acids.
Tucci S; Behringer S; Spiekerkoetter U
FEBS J; 2015 Nov; 282(21):4242-53. PubMed ID: 26284828
[TBL] [Abstract][Full Text] [Related]
8. Tissue-specific strategies of the very-long chain acyl-CoA dehydrogenase-deficient (VLCAD-/-) mouse to compensate a defective fatty acid β-oxidation.
Tucci S; Herebian D; Sturm M; Seibt A; Spiekerkoetter U
PLoS One; 2012; 7(9):e45429. PubMed ID: 23024820
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Metabolic Defects in Fatty Acid Oxidation Using Peripheral Blood Mononuclear Cells Loaded with Deuterium-Labeled Fatty Acids.
Yuasa M; Hata I; Sugihara K; Isozaki Y; Ohshima Y; Hara K; Tajima G; Shigematsu Y
Dis Markers; 2019; 2019():2984747. PubMed ID: 30881520
[TBL] [Abstract][Full Text] [Related]
10. Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.
Gillingham MB; Heitner SB; Martin J; Rose S; Goldstein A; El-Gharbawy AH; Deward S; Lasarev MR; Pollaro J; DeLany JP; Burchill LJ; Goodpaster B; Shoemaker J; Matern D; Harding CO; Vockley J
J Inherit Metab Dis; 2017 Nov; 40(6):831-843. PubMed ID: 28871440
[TBL] [Abstract][Full Text] [Related]
11. Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.
Yamada K; Taketani T
J Hum Genet; 2019 Feb; 64(2):73-85. PubMed ID: 30401918
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of long-chain fatty acid oxidation disorders using alternative precursors and acylcarnitine profiling in fibroblasts.
Roe DS; Yang BZ; Vianey-Saban C; Struys E; Sweetman L; Roe CR
Mol Genet Metab; 2006 Jan; 87(1):40-7. PubMed ID: 16297647
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of 3-hydroxy-fatty acids in the culture medium of long-chain L-3-hydroxyacyl CoA dehydrogenase (LCHAD) and mitochondrial trifunctional protein-deficient skin fibroblasts: implications for medium chain triglyceride dietary treatment of LCHAD deficiency.
Jones PM; Butt Y; Bennett MJ
Pediatr Res; 2003 May; 53(5):783-7. PubMed ID: 12621125
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of bezafibrate in two patients with mitochondrial trifunctional protein deficiency.
Suyama T; Shimura M; Fushimi T; Kuranobu N; Ichimoto K; Matsunaga A; Takayanagi M; Murayama K
Mol Genet Metab Rep; 2020 Sep; 24():100610. PubMed ID: 32509533
[TBL] [Abstract][Full Text] [Related]
15. Unique plasma metabolomic signatures of individuals with inherited disorders of long-chain fatty acid oxidation.
McCoin CS; Piccolo BD; Knotts TA; Matern D; Vockley J; Gillingham MB; Adams SH
J Inherit Metab Dis; 2016 May; 39(3):399-408. PubMed ID: 26907176
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial fatty acid beta-oxidation in the human eye and brain: implications for the retinopathy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.
Tyni T; Paetau A; Strauss AW; Middleton B; Kivelä T
Pediatr Res; 2004 Nov; 56(5):744-50. PubMed ID: 15347768
[TBL] [Abstract][Full Text] [Related]
17. Substrate oxidation and cardiac performance during exercise in disorders of long chain fatty acid oxidation.
Behrend AM; Harding CO; Shoemaker JD; Matern D; Sahn DJ; Elliot DL; Gillingham MB
Mol Genet Metab; 2012 Jan; 105(1):110-5. PubMed ID: 22030098
[TBL] [Abstract][Full Text] [Related]
18. Triheptanoin: long-term effects in the very long-chain acyl-CoA dehydrogenase-deficient mouse.
Tucci S; Floegel U; Beermann F; Behringer S; Spiekerkoetter U
J Lipid Res; 2017 Jan; 58(1):196-207. PubMed ID: 27884962
[TBL] [Abstract][Full Text] [Related]
19. Physiological Perspectives on the Use of Triheptanoin as Anaplerotic Therapy for Long Chain Fatty Acid Oxidation Disorders.
Sklirou E; Alodaib AN; Dobrowolski SF; Mohsen AA; Vockley J
Front Genet; 2020; 11():598760. PubMed ID: 33584796
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
